The Impact of Timing on Heart Failure Treatment Success

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Diagnosis and prescribing are no longer on the margins for pharmacy practice, but explicitly called out in the ACPE Standards that guide pharmacy education. Once considered out of bounds for pharmacists, diagnostic reasoning is now central to preparing practice-ready graduates. This episode explores how preceptors can support learners in applying clinical decision-making frameworks, integrating shared decision-making, and navigating prescriptive authority across diverse practice settings—equipping the next generation of pharmacists for expanded patient care.HOSTKathy Schott, PhDVice President, Education & OperationsCEimpactGUESTSJennifer Adams, PharmD, EdDAssociate Professor, Associate Dean for Academic AffairsIdaho State University L.S. Skaggs College of PharmacyRachel AllenAssociate Teaching ProfessorUniversity of Washington School of PharmacyCherith Smith, PharmDClinical Assistant Professor and Director, Experiential EducationUniversity of Montana – College of Health Skaggs School of PharmacyKathy Schott, Jennifer Adams, Rachel Allen, and Cherith Smith have no relevant financial relationships with ineligible companies to disclose. Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!CPE INFORMATIONLearning ObjectivesAt the end of this course, preceptors will be able to:1. Describe key principles of diagnostic reasoning and prescribing within the context of pharmacy practice.2. Identify evidence-based frameworks such as the One-Minute Preceptor and shared decision-making to support learner development in clinical settings.0.05 CEU/0.5 HrUAN: 0107-0000-25-319-H99-PInitial release date: 10/15/2025Expiration date: 10/15/2028Additional CPE details can be found here.This program has been:Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.Follow CEimpact on Social Media:LinkedInInstagram

As questions continue to surface about the potential link between prenatal acetaminophen use and autism spectrum disorder, pharmacists must be prepared to address patient concerns with confidence and clarity. This episode explores the current body of evidence, public health messaging, and practical strategies for counseling during pregnancy. Tune in to strengthen your knowledge and support safe, evidence-informed guidance for your patients.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJohn Swegle, PharmDClinical Associate ProfessorUniversity of Iowa College of PharmacyJoshua Davis Kinsey and John Swegle have no relevant financial relationships with ineligible companies to disclose.  Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize current evidence regarding the association between prenatal acetaminophen exposure and autism spectrum disorder.2. Identify patient counseling considerations for the safe use of acetaminophen during pregnancy.0.05 CEU/0.5 HrUAN: 0107-0000-25-310-H01-PInitial release date: 10/13/2025Expiration date: 10/13/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Allergic reactions can range from a bothersome nuisance to a life-threatening emergency, making it crucial for pharmacists to stay informed about current treatment options and best practices. This episode discusses common triggers, effective therapies—from antihistamines and injections to the newly approved epinephrine nasal spray—and key counseling strategies to ensure patients receive safe, prompt relief. Tune in to improve your preparedness and support confident, patient-centered care.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactRachel Maynard, PharmDLead EditorPyrlsJoshua Davis Kinsey and Rachel Maynard have no relevant financial relationships to disclose. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common triggers and clinical features associated with allergic reactions.2. Describe available treatment options for allergic reactions, including newly approved therapies and their appropriate use.0.05 CEU/0.5 HrUAN: 0107-0000-25-300-H01-PInitial release date: 10/6/2025Expiration date: 10/6/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

With numerous new medications launching each year, pharmacists play a vital role in translating complex drug information into practical, patient-centered care. This episode offers a brief overview of select FDA-approved drugs from the past year, highlighting their therapeutic importance, key considerations, and clinical uses. Whether counseling patients or working with healthcare providers, pharmacists need to stay informed about what’s new—and understand its impact on practice.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJoe Strain, PharmDProfessor of Pharmacy PracticeSouth Dakota State University/Monument Health Rapid City HospitalJoshua Davis Kinsey and Joe Strain have no relevant financial relationships to disclose. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. List unique pharmacological properties for select newly approved medications.2. Recognize important safety considerations, including adverse effects, interactions, and monitoring parameters, for each featured drug.0.05 CEU/0.5 HrUAN: 0107-0000-25-295-H01-PInitial release date: 9/29/2025Expiration date: 9/29/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

The FDA remains a powerful driver of change in pharmacy practice through its approvals, policies, and public health actions. This episode highlights timely FDA developments and emerging areas of focus that pharmacists need to be aware of—from regulatory shifts to new communication initiatives. Tune in to stay informed on FDA activity that could influence the way you practice and care for patients.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTMary Ross Southworth, PharmDPrincipalS&S Consulting PartnersJoshua Davis Kinsey has no relevant financial relationships to disclose. Mary Ross Southworth is a consultant for Travere, Unicycive, Liquidia, and Mineralys. All relevant financial relationships have been mitigated.  Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Recognize current FDA topics and areas of focus relevant to pharmacy practice.2. Describe how current FDA priorities may impact medication use, pharmacist responsibilities, or patient care.0.05 CEU/0.5 HrUAN: 0107-0000-25-296-H03-PInitial release date: 9/22/2025Expiration date: 9/22/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

As more patients live beyond cancer treatment, survivorship care is becoming an essential—but often overlooked—part of the healthcare journey. This episode explores how pharmacists can support survivors through medication management, mental health awareness, lifestyle counseling, and connection to broader care resources. Tune in to learn how you can play a meaningful role in helping patients navigate life after cancer.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErica Marchese, PharmD, BCPS, BCOP, BCSCP, MHAClinical Pharmacy Program DirectorCity of HopeJoshua Davis Kinsey and Erica Marchese have no relevant financial relationships to disclose.Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common physical, emotional, and medication-related challenges faced by patients in the survivorship phase of cancer care.2. Describe the pharmacist's role in supporting survivorship through medication review, lifestyle counseling, and care coordination.0.05 CEU/0.5 HrUAN: 0107-0000-25-292-H01-PInitial release date: 9/15/2025Expiration date: 9/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Falls are a leading cause of injury and death in older adults, and pharmacists are in a key position to help prevent them. This episode highlights how to identify medication risks, share practical prevention strategies, and connect patients with trusted tools and resources. Tune in to learn how you can make a meaningful impact in reducing falls in your community. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKristin Meyer PharmD, BCGP, FASCPProfessor of Pharmacy PracticeDrake University College of Pharmacy and Health SciencesJoshua Davis Kinsey and Kristin Meyer have no relevant financial relationships to disclose. RESOURCESNational Council on Aging (NCOA) Falls PreventionNCOA Falls Prevention Awareness WeekNCOA Falls Free CheckUp®CDC STEADIPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common medication classes and household hazards associated with increased fall risk in older adults.2. Describe the pharmacist's role in fall prevention through medication review, patient education, and community engagement.0.05 CEU/0.5 HrUAN: 0107-0000-25-269-H05-PInitial release date: 9/8/2025Expiration date: 9/8/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

With shifting policies, payment models, and an unpredictable respiratory virus landscape,  pharmacy teams need more than clinical updates to prepare for the upcoming immunization season. This episode explores key issues shaping immunization practice today — including policy changes, billing and documentation trends, and how teams can proactively adapt and advocate for their role. Tune in for timely insights that go beyond the clinical headlines and complement our in-depth, on-demand course, Annual Immunization Update 2025. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTElizabeth Skoy, PharmDProfessorNorth Dakota State University Joshua Davis Kinsey and Elizabeth Skoy have no relevant financial relationships to disclose. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Recognize recent policy and reimbursement updates that influence pharmacy-based immunization services and their potential to improve patient access to care.2. Identify strategies pharmacy teams can use to prepare for the 2025-26 respiratory virus season in ways that support timely, equitable, and effective patient immunization.0.05 CEU/0.5 HrUAN: 0107-0000-25-286-H01-PInitial release date: 9/1/2025Expiration date: 9/1/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Low-dose naltrexone (LDN) is generating growing interest as a potential therapy for conditions such as chronic pain and immune-related disorders. This episode offers a foundational overview of what LDN is, how it’s thought to work, where current evidence stands, and how pharmacists may encounter it in practice. Learn what pharmacists need to know to confidently approach patient questions about LDN and how it fits into current conversations in pharmacy and patient care. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTMichelle Moser, RPhRetired Compounding PharmacistJoshua Davis Kinsey has no relevant financial relationships to disclose.Michelle Moser was a volunteer board member for LDN Research Trust (ended June 2025), a board member for Alliance for Pharmacy Compounding (ended September 2024), and an employee of Revelation Pharma (ended June 2024). All relevant financial relationships have been mitigated.   Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Define low-dose naltrexone (LDN) and describe how it differs from traditional naltrexone dosing.   2. Identify proposed mechanisms of action and areas of emerging interest related to LDN use in practice.0.05 CEU/0.5 HrUAN: 0107-0000-25-275-H01-PInitial release date: 8/25/2025Expiration date: 8/25/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram